Peptide Category Comparison: Glucagon vs Insulin Key Differences
Abstract: Glucagon and insulin, key peptide hormones, exhibit opposing metabolic roles: insulin lowers blood glucose via cellular uptake, while glucagon raises it through glycogenolysis. Market trends show insulin analogs dominating diabetes care (USD 23B in 2023), with glucagon gaining traction in hypoglycemia rescue and weight management. Brand comparisons (e.g., Novo Nordisk vs. Eli Lilly) highlight insulin’s superior stability and glucagon’s shorter shelf-life. Technical advantages include insulin’s precise dosing via pens/pumps versus glucagon’s rapid onset but formulation challenges. Regulatory certifications (FDA/EMA) are critical for quality. Selection tips prioritize purity (>98%), cold-chain logistics, and indication-specific formulations. Industry growth (CAGR 8.5%) underscores expanding applications in metabolic disorders.